Trial Profile
A pilot non-inferiority immunogenicity single blind randomised study of two human papillomavirus vaccines administered intradermally to females aged 10 to 15 years, 18 to 26 years and 36 to 45 years to bridge previous efficacy findings of intramuscularly administered vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 12 Jun 2013 Status changed from not yet recruiting to completed.
- 13 May 2009 Status changed from not stated to not yet recruiting.
- 13 May 2009 New trial record